NASDAQ$AGEN
Agenus Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results and provided a corporate update.
Agenus reported revenue of $28 million and a net loss of $74 million for the fourth quarter of 2022. The company ended the year with a cash, cash equivalent, and short-term investment balance of $193 million.
- Agenus entered 2023 with strong momentum across its clinical pipeline of immuno-oncology programs.
- Botensilimab and balstilimab show exciting potential in combination to treat a broad spectrum of treatment-resistant cancers.
- Botensilimab's clinical activity in advanced and refractory cancers has generated considerable interest from experts worldwide.
- Agenus is expediting the expansion of its botensilimab/balstilimab development program in MSS CRC and other priority indications.
Headline financials
Revenue & EPS history
Agenus · Revenue · Quarterly
$28.4M
Forward guidance
Agenus is focused on advancing its clinical pipeline and strategic partnerships in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+0.7%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+5.4%
Avg return
30 days after
49%
31 / 63 earnings
Positive
+39.9%
Q4 2011
Best reaction
-22.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -14.9% | -6.3% | -19.9% | |
| Q4 2025 | +5.8% | +19.7% | +55.8% | |
| Q3 2025 | +6.3% | +9.0% | +2.8% | |
| Q1 2025 | +20.3% | +19.6% | +77.3% | |
| Q4 2024 | -4.7% | -13.5% | -24.7% | |
| Q3 2024 | -22.3% | -30.3% | -21.0% | |
| Q2 2024 | +0.2% | -7.3% | -2.6% | |
| Q1 2024 | -11.4% | -19.0% | +27.9% | |
| Q4 2023 | -18.0% | -15.2% | -38.3% | |
| Q3 2023 | +7.5% | -16.7% | +3.8% | |
| Q2 2023 | -5.9% | -0.7% | -7.4% | |
| Q1 2023 | -3.1% | -10.7% | +28.3% | |
| Q4 2022 | +10.5% | -0.6% | -12.3% | |
| Q3 2022 | -15.5% | +5.0% | +5.0% | |
| Q2 2022 | +2.3% | +13.8% | +0.4% | |
| Q1 2022 | -0.7% | +7.2% | +7.9% | |
| Q4 2021 | +13.7% | +7.8% | -8.9% | |
| Q3 2021 | +3.6% | -7.2% | -23.2% | |
| Q2 2021 | -0.4% | +9.2% | +13.0% | |
| Q1 2021 | +4.2% | +5.1% | +36.6% | |
| Q4 2020 | -3.0% | -6.3% | -18.7% | |
| Q3 2020 | +0.0% | +4.9% | +0.5% | |
| Q2 2020 | +12.3% | +5.7% | +17.4% | |
| Q1 2020 | -4.2% | -3.0% | +45.8% | |
| Q4 2019 | -7.4% | -20.6% | -8.1% | |
| Q3 2019 | +13.3% | +25.3% | +38.2% | |
| Q2 2019 | +17.8% | +24.7% | +41.6% | |
| Q1 2019 | +7.5% | +10.2% | +1.5% | |
| Q4 2018 | -3.0% | +1.0% | -12.2% | |
| Q3 2018 | +10.1% | +5.9% | +25.0% | |
| Q2 2018 | +4.6% | +3.5% | +16.8% | |
| Q1 2018 | -14.1% | -3.3% | -14.4% | |
| Q4 2017 | +2.1% | -1.6% | -18.7% | |
| Q3 2017 | -4.4% | +1.6% | -1.4% | |
| Q2 2017 | -2.4% | -6.6% | -9.7% | |
| Q1 2017 | +10.5% | +10.5% | +2.3% | |
| Q4 2016 | +3.9% | +0.3% | -14.9% | |
| Q3 2016 | -21.8% | -26.0% | -7.1% | |
| Q2 2016 | +12.6% | +12.6% | +26.2% | |
| Q1 2016 | -16.2% | — | — | |
| Q4 2015 | +19.6% | — | — | |
| Q3 2015 | -5.4% | — | — | |
| Q2 2015 | -7.4% | — | — | |
| Q1 2015 | +17.1% | — | — | |
| Q3 2014 | -2.9% | — | — | |
| Q2 2014 | +6.2% | — | — | |
| Q1 2014 | -5.2% | — | — | |
| Q4 2013 | +0.4% | — | — | |
| Q3 2013 | +2.8% | — | — | |
| Q2 2013 | +1.0% | — | — | |
| Q1 2013 | +1.1% | — | — | |
| Q4 2012 | +4.6% | — | — | |
| Q3 2012 | -7.2% | — | — | |
| Q2 2012 | -4.2% | — | — | |
| Q1 2011 | -3.9% | — | — | |
| Q1 2012 | +6.7% | — | — | |
| Q4 2011 | +39.9% | — | — | |
| Q3 2011 | -3.7% | — | — | |
| Q2 2011 | -16.2% | — | — | |
| Q4 2010 | -4.0% | — | — | |
| Q3 2010 | -5.2% | — | — | |
| Q2 2010 | -1.2% | — | — | |
| Q1 2010 | +14.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro